DEH113
Phase 3Small molecule
DEH113 is one of 25 small molecule programs targeting Dysmenorrhea. It is currently in Phase 3.
1
Indications
2
Total Trials
2
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Dysmenorrhea
#DrugCompanyPhaseTrials
1Aleve
Jazz PharmaceuticalsApproved
Voltaren
NovartisApproved
Voltaren
NovartisApproved
Estrace
Novo NordiskApproved
Bayer Aspirin
BayerApproved
Tylenol
KKenvue Brands
Approved
Bextra
TThe Searle Company Limited Pakistan
Approved
Ultram
WWim Janssens
Approved
Oruvail
WWyeth-Lederle Vaccines
Approved
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DEH113. EMBL-EBI & Wellcome Sanger Institute.
- [4]